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Introduction: Estrogen inhibition is effective in preventing breast cancer in only up to 50% of women with
precancerous lesions and many experience side effects that are poorly tolerated. As insulin-like growth factor I
(IGF-I) underlies both estrogen and progesterone actions and has other direct effects on mammary development
and carcinogenesis, we hypothesized that IGF-I inhibition might provide a novel approach for breast cancer
chemoprevention.
Methods: In total, 13 women with core breast biopsies diagnostic of atypical hyperplasia (AH) were treated for
10 days with pasireotide, a somatostatin analog which uniquely inhibits IGF-I action in the mammary gland. They
then had excision biopsies. 12 patients also had proliferative lesions and one a ductal carcinoma in situ (DCIS).
Primary outcomes were changes in cell proliferation and apoptosis after treatment. Expression of estrogen receptor
(ER), progesterone receptor (PR), and phosphorylated Insulin-like growth factor I receptor (IGF-1R), protein kinase B
(AKT) and extracellular signal-regulated kinases 1/2 (ERK1/2) were also assessed. Core and excision biopsies from
14 untreated patients served as non-blinded controls. Hyperglycemia and other side effects were carefully monitored.
Results: Pasireotide decreased proliferation and increased apoptosis in all AH (from 3.6 ± 2.6% to 1.3 ± 1.2% and from
0.3 ± 0.2% to 1.5 ± 1.6%, respectively) and proliferative lesions (from 3.8 ± 2.5% to 1.8 ± 1.8% and from 0.3 ± 0.2% to
1.3 ± 0.6%, respectively). The DCIS responded similarly. ER and PR were not affected by pasireotide, while IGF-1R, ERK1/2
and AKT phosphorylation decreased significantly. In contrast, tissue from untreated controls showed no change in cell
proliferation or phosphorylation of IGF-1R, AKT or ERK 1/2. Mild to moderate hyperglycemia associated with reduced
insulin levels was found. Glucose fell into the normal range after discontinuing treatment. Pasireotide was well tolerated
and did not cause symptoms of estrogen deprivation.
Conclusions: IGF-I inhibition by pasireotide, acting through the IGF-1R, was associated with decreased proliferation
and increased apoptosis in pre-malignant breast lesions and one DCIS. Assuming hyperglycemia can be controlled,
these data suggest that inhibiting the IGF-I pathway may prove an effective alternative for breast cancer chemoprevention.
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Breast cancer is one of the most frequently diagnosed
tumors worldwide. Randomized controlled trials demon-
strated the preventive effects of tamoxifen and raloxifene
in women at increased risk [1-3]. These studies have led
to the practice of employing selective estrogen receptor
modulators (SERMs) for breast cancer chemoprevention.
However, a number of side effects limit their use, in-
cluding climacteric symptoms in premenopausal women,
thromboembolic phenomena, and for tamoxifen, endo-
metrial hyperplasia and carcinoma. The compliance rate
with anti-estrogen therapy in the chemopreventive setting
has been reported to be as low as 20% [4]. Breast cancer
can be prevented in up to 50% of patients with high- risk
lesions. Therefore, targeted estrogen inhibition is only
partially effective. Alternative more effective medical ap-
proaches are highly desirable.
Insulin-like growth factor I (IGF-I) affects mammary
development in at least two ways. It has an independent
effect on ductal morphogenesis and is also essential for
estrogen and progesterone action in the mammary gland
[5-7]. Furthermore, IGF-I plays a pivotal role in the
multi-step process that leads from normal breast tissue
to hyperplasia and then carcinoma [8]. Based on these
actions, we hypothesized that IGF-I inhibition would
prevent breast cancer development. Indeed, published
[9] and as yet unpublished data from our laboratory have
shown that blockade of IGF-I action in the mammary
gland prevents the development of premalignant mam-
mary lesions in different mouse models [9-11]. In these
experiments, we used a novel multi-ligand somatostatin
analog, pasireotide, which not only inhibits growth hor-
mone secretion from the pituitary and thereby, serum
IGF-I, but also specifically targets IGF-I action within
the mammary gland [12]. To translate the findings in
rodents to humans, we conducted the present study,
aimed at assessing the effect of IGF-I inhibition with pasir-
eotide on premalignant lesions of the breast. Treatment
with pasireotide caused a decrease in cell proliferation and
an increase in apoptosis in all cases evaluated. Based on
these results, we conclude that IGF-I inhibition may rep-
resent a novel strategy to prevent breast cancer.
Methods
Study setting
This study was conducted at the Clinical Cancer Center,
the Clinical Translational Science Institute, the Immuno-
histochemistry and Histopathology Cores, and the BioRe-
pository Center of the New York University (NYU) School
of Medicine, and at the Department of Veterans Affairs
Medical Center, New York, NY in accordance with the
Helsinki Declaration. It was approved by the Institutional
Review Board (IRB) at the NYU School of Medicine, the
NYU Cancer Center Protocol Review and MonitoringCommittee (PRMC) and the Department of Defense;
Human Research Protection Office (HRPO), Office of
Research Protections (ORP), United States Army Medical
Research and Materiel Command (USAMRMC), the United
States Food and Drug Administration (FDA), Novartis
Pharmaceuticals and the Veterans Administration Office
of Research and Development and Human Subjects Com-
mittee. The clinical trial number was NCT01372644.
Participants
The trial included women who were diagnosed with
atypical hyperplasia (AH) of the breast (atypical ductal
hyperplasia (ADH) or atypical lobular hyperplasia/lobu-
lar carcinoma in situ (ALH/LCIS)) by core biopsy of lesions
discovered by mammography (mass, density, calcifications).
To be eligible, participants had to be over 21 years of age,
be otherwise healthy, and be accessible for follow up. Pa-
tients in whom invasive breast cancer coexisted with AH
or who had received tamoxifen or other anti-estrogens
within the previous 6 months were excluded. Women
with abnormal fasting plasma glucose or a QT interval
longer than 450 msec were also excluded. Fifteen patients
were enrolled and 13 completed the trial (Figure 1). Writ-
ten informed consent was obtained from all.
Procedures
IGF-I inhibition was achieved by treatment with 600 μg
pasireotide (Novartis, Basel, Switzerland) subcutaneously
injected twice daily for ten days. The patients self-injected
the medication according to the instructions received
at study entrance. They were also trained to measure
finger-stick glucose with an Ascensia Contour® gluc-
ometer (Bayer Health Care, Mishawaka, IN, USA) and to
follow a low carbohydrate diet. The day before starting the
treatment, participants underwent a baseline evaluation
comprising a complete medical examination, basic blood
tests, and measurement of fasting insulin, HbA1c, and
IGF-I. During the 10-day treatment period, patients moni-
tored fasting glucose by finger stick every day and also
attended the study center between days 3 and 7 for
additional safety assessment. Women who had fasting
finger-stick glucose >120 mg/dL were asked to monitor
glucose four times a day. On the tenth day they underwent
standard-of-care excision biopsies with pre-operative wire
placement. Women who had glucose levels ≥110 mg/dL
at the end of treatment were asked to continue to monitor
finger-stick glucose until glucose was normalized. Follow-
up assessments were done 7 to 9 days, 20 to 25 days, and
3 months after the last injection of pasireotide (coinciding
with the day of surgery) (Figure 1).
Both the core and excision biopsies were reviewed by
a breast pathologist to confirm diagnosis. One patient
who had ductal carcinoma in situ (DCIS) in addition to
AH was inadvertently included in the trial. Twelve of
15 patients enrolled
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Figure 1 Trial profile. IGF, insulin-like growth factor; s.c., subcutaneous.
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(usual ductal hyperplasia, sclerosing adenosis, small ductal
papilloma, radial scar). The effects of pasireotide on these
lesions were also analyzed.
Immunohistochemistry
Proliferation and apoptosis in epithelial cells were assessed
by comparing formalin-fixed paraffin-embedded tissue
sections of the core and excision biopsies. To reduce the
possibility of chance effects, we also determined prolifera-
tion in core and excision biopsies from non-blinded pa-
tients who were not treated. Blocks were retrieved from
the BioRepository Center of the NYU School of Medicine.Proliferating cells were identified by immunohistochem-
istry for Ki67 [9]. Slides were incubated with Novocastra
rabbit polyclonal anti-Ki67 antibodies (Leica Biosystems,
Newcastle Upon Tyne, UK) and horseradish peroxidase
(HRP)-conjugated goat anti-rabbit secondary antibodies
(Dako, Carpinteria, CA, USA) and a 3,3’-diaminobenzi-
dine (DAB) solution (Vector Laboratories, Burlingame,
CA, USA) were used to detect the bound primary anti-
bodies. The latter were omitted in negative controls.
Apoptosis was demonstrated by terminal deoxynucleotidyl
transferase (TdT) dUTP nick end labeling (TUNEL) [9].
This technique is based on the activity of the TdT enzyme,
which labels the fragmented DNA of apoptotic cells for
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study TUNEL was performed using the ApopTag® kit
(EMD Millipore, Billerica, MA, USA). Negative control tis-
sue samples were not incubated with TdT.
The expression of estrogen receptor (ER) and progester-
one receptor (PR) was also determined by immunohis-
tochemistry with rabbit monoclonal primary antibodies
(Thermo Fisher Scientific, Waltham, MA, USA). Bio-
tinylated anti-rabbit secondary antibodies, followed by
streptavidin-HRP conjugate and DAB, were used for
detection. Stained sections were imaged on a light micro-
scope with Nikon ACT-1 software. For each lesion, the
percentage of Ki67-positive, TUNEL-positive, ER-positive,
and PR-positive cells was counted out of a total of 200 epi-
thelial cells.
After completing the immunostaining for Ki67, ER,
and PR and the TUNEL, there was good-quality tissue
left for further staining in five cases only for phosphory-
lated AKT and ERK 1/2 and four cases for phosphory-
lated IGF-1R in both core and excision biopsies. Sections
were stained for phosphorylated AKT (Ser473) and phos-
phorylated ERK 1/2 (Thr202/Tyr204) by using rabbit
monoclonal primary antibodies (Cell Signaling Technolo-
gies, Danvers, MA, USA) and biotinylated anti-rabbit
secondary antibodies, streptavidin-HRP, and DAB for
detection. Phosphorylation of AKT and ERK 1/2 was also
assessed in the control samples from untreated patients.
As the intensity of the immunostaining for phosphory-
lated AKT and ERK1/2 was heterogeneous, an intensity
score (from 0 to 3) and a percentage score were ascer-
tained for each lesion. A final score was then calculated by
applying the following formula:
percentage of weakly stained cells  1ð Þ
þ percentage of moderately stained cells  2ð Þ
þ percentage of strongly stained cells  3ð Þ:
Immunofluorescence for phosphorylated IGF-1R was
performed using rabbit anti p-IGF-1R (Y1161) (Abcam,
Cambridge, MA, USA) as primary antibody and a sec-
ondary antibody obtained from Donkey anti rabbit
Alexa 488 (Life technologies, Grand Island, NY, USA).
To quantify the phosphorylated IGF-1R (Y1161) ten
images per case, which included glandular tissue, were
randomly imaged using 40× objective with 0.95 nu-
merical aperture Zeiss Plan-Apochromat objective on
a Zeiss Axionvert equipped with epifluorescence. Mean
intensity was evaluated for each treatment on twelve-bit
images using in-home developed macros for the open
source platform Fiji-ImageJ (NIH, Bethesda, MD, USA).
Statistical analysis
Descriptive statistics are presented as mean and SD
and changes from before (core biopsy) to after (excisionbiopsy) treatment as both the actual arithmetic difference
and the percent change relative to pre-treatment. Relative
percent change is the preferred statistic, because it is ad-
justed for the before-biopsy value (for example, a decrease
in Ki-67 from 5% to 4% is a 1% arithmetic decrease, but a
20% relative decrease). The primary endpoints were the
changes and relative changes in cell proliferation and
apoptosis from the core to the excision biopsies. The
evaluation of ER and PR status before and after treatment
was the secondary pre-specified endpoint.
Due to the small sample size, a non-parametric ap-
proach was taken and the Wilcoxon signed rank (WSR)
test was used to analyze the study outcomes. The sign
test was also used to determine whether directionality of
change differed from chance. Analysis was conducted
separately on proliferative lesions and AH lesions. Two
pathologists blinded to patient status read the slides for
Ki67 and apoptosis. After that, one left the institution
and the remaining slides (PR, ER, phosphorylated AKT
and ERK 1/2) were analyzed only by the other patholo-
gist. The paired t-test and repeated-measures analysis of
variance (ANOVA) were used to compare the scores for
phosphorylated AKT and ERK 1/2 before and after treat-
ment and pIGF-1R by fluorescence. Blood concentra-
tions of glucose, insulin, and IGF-I across study visits,
respectively were also analyzed. In a separate sub-study,
we demonstrated excellent inter-rater agreement between
two pathologists who, blinded to one another, evaluated
Ki-67 in 12 treated patients and 23 controls.Role of the funding source
Neither the funding source nor the provider of the
medication had any role in the design or conduct of the
study, or in the collection, analysis, and interpretation of
the data. The corresponding author had full access to all
data and had final responsibility for the decision to sub-
mit for publication.Results
Patients
All patients were Caucasian. Mean age was 55.9 ± 6.2
years. Four women had ADH, three had a combination
of ADH and ALH/LCIS, five had ALH/LCIS, and one
had ALH/LCIS and DCIS. Some AH lesions were entirely
removed with the core biopsy. However, those cases had
remaining areas of proliferative disease in both core and
excision biopsies that permitted evaluation of the effects
of pasireotide. In all, there were twelve proliferative
lesions, five ALH/LCIS, one ADH, and one DCIS
available for assessment of the study endpoints. Control
samples from untreated patients included ten proliferative
and five AH lesions from 14 women whose mean age was
49.8 ± 6.9 years.
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Compared with pre-treatment core biopsies, pasireotide
caused a reduction in cell proliferation in all proliferative
and AH lesions in the excision biopsies (WSR, P = 0.001
and P = 0.031 respectively) (Figure 2A). On average,
Ki67-positive cells decreased by 66.5% in proliferative
lesions and by 56.7% in areas of AH. Cell prolifera-
tion also decreased by 73.5% (from 3.4% to 0.9%) in the
DCIS lesion (Figure 3B).
The percentage of Ki67-positive cells decreased in six of
the ten control proliferative lesions (sign test, P = 0.29)
and overall it did not significantly vary between the core
and excision biopsies (mean change −1.2 ± 7.5%; WSR,
P = 0.54). Similarly a reduction in proliferation wasFigure 2 Effect of treatment with pasireotide on cell proliferation and
pasireotide on proliferation rate as assessed by immunohistochemistry for
assessed by terminal deoxynucleotidyl transferase dUTP nick end labeling (
the breast before and after 10 days of treatment with pasireotide.observed in two out of five AH lesions from untreated pa-
tients (Figure 2B). These decreases were not significantly
different from the hypothesis of random change (sign test,
P = 1.00 and P = 0.77, respectively), nor was the mean
percentage of Ki67-positive cells significantly different in
core versus excision biopsies (1.1 ± 5.2%, WSR P = 0.44 for
AH and -0.6 ± 16.1%, WSR P = 0.97 for DCIS), (Figure
3C-D). These results represent the work of pathologist BS.
Effect on apoptosis
An increase in apoptosis was found in all proliferative
and AH lesions upon treatment with pasireotide (WSR,
P = 0.001 and WSR, P = 0.031, respectively; Figure 4A-C),
as well as in the DCIS (from 0.1% to 0.4%; Figure 4D).apoptosis in pre-malignant lesions of the breast. Effects of
Ki67 in 12 proliferative (A) and 6 atypical hyperplasia (B) Apoptosis, as
TUNEL), in 11 proliferative (C) and 6 atypical hyperplasia (D) lesions of
Figure 3 Representative images of proliferation (Ki67) and apoptosis (terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL)) from patients treated with pasireotide. Representative examples showing Ki67 immunostaining of atypical hyperplasia (A) and one case
of ductal carcinoma in situ (DCIS) (B) from pasireotide-treated patients (top panel). (C) TUNEL staining of an atypical lobular hyperplasia (ALH) lesion
before and after treatment with pasireotide. Positive cells are brown. (D) A small increase in the number of apoptotic cells (arrows) was also observed
after treatment in one case of DCIS.
Singh et al. Breast Cancer Research 2014, 16:463 Page 6 of 12
http://breast-cancer-research.com/content/16/6/463Effects on ER and PR
Pasireotide had no significant effect on ER or PR. Effects
of pasireotide on ER and PR are shown in Table 1 and
Figure 4.
Mechanism of action of pasireotide
We recently reported that pasireotide inhibited cell
proliferation and increased apoptosis in a model of ratFigure 4 Effect of pasireotide on the estrogen and progesterone rece
estrogen receptor (ER) (A) or progesterone receptor (PR) (B) before and aftmammary hyperplasia induced by hGH+ E2 by blockade
of the IGF-I receptor, as measured by a reduction in pIRS1
[9]. To determine if pasireotide also worked through that
mechanism in women with atypical hyperplasia we mea-
sured the effect of pasireotide on phospho IGF-1R expres-
sion, as measured by intensity of immunofluorescence,
and found that it was significantly lowered in excision
biopsies after treatment compared to pre-treatment coreptor. No significant differences were observed in the levels of
er treating with pasireotide.
Table 1 Changes in the expression of estrogen receptor (ER) and progesterone receptor (PR) following treatment with
pasireotide
Number Change in percentage
of positive cells
P-value Number of lesions in which the
percentage of positive cells decreased
P-value
Proliferative lesions
ER 9 −4.2 ± 9.9 0.13 7 (77.8%) 0.18
PR 7 −9.8 ± 30.7 0.81 3 (42.9%) 1.00
Atypical hyperplasia
ER 5 −8.0 ± 15.0 0.31 2 (40%) 1.00
PR 4 −10.7 ± 54.3 0.88 2 (50%) 1.00
Differences in the percentage of positive cells in core versus excision biopsies are presented as mean ± SD.
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sion biopsies in untreated patients served as controls
(Figure 5).
Phosphorylated AKT and ERK 1/2 were also affected in
five proliferative, two ALH/LCIS, and one ADH from five
women. Both the number of positive cells and the intensity
of the staining were lower in excision than in core biopsies
(Figure 6).
Effects on glucose, insulin, HgbA1c and IGF-I and side effects
Among the 14 treated patients, 11 (78.6%) had grade 1
nausea and seven (50%) grade 1 diarrhea. Both adverse
events were transient. Side effects of estrogen inhibitors,Figure 5 Effect of treatment with pasireotide on phospho insulin-like gr
of phospho IGF-1R by immunofluorescence in four patients with atypical hype
(B). Representative sections from one of the patients before (C) and after treatmsuch as hot flashes, night sweats, decreased libido, and
vaginal dryness, were not reported. Mean fasting finger-
stick glucose rose from the baseline value of 97.8 ± 14.2
mg/dL to a peak of 133.2 ± 23.9 mg/dL (Figure 7). On
average the highest glucose value was reached seven
days after the first injection of pasireotide. One patient
was withdrawn from the study after her postprandial
capillary glycemia reached 226 mg/dL. Four out of
the thirteen study participants had fasting finger-stick
glucose values ≥110 mg/dL on the last day of treatment.
Their mean glucose decreased from 162.8 ± 21.2 mg/dL to
100.5 ± 18.8 mg/dL in one day, and by three days
after drug discontinuation it was 92.0 ± 16.2 mg/dL. Anowth factor -1 receptor (IGF-1R). Effect of pasireotide on mean intensity
rplasia before and after treatment with pasireotide (A) and five controls










































Figure 6 Effect of treatment with pasireotide on phospho AKT and ERK1/2. (A) The mean intensity index was decreased by pasireotide
from 42.5 ± 14 to 9.37 ± 3 after treatment as measured in eight patients. (B) Similar effects were observed with phospho ERK1/2 with a mean
intensity index of 218 ± 29 before to 100 ± 18 after treatment, measured in six patients. Control tissues were not affected for p-AKT (C) or p-ERK
1/2 (D).
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cose after day 10. Overall, fasting glucose was 98.7 ± 13.4
mg/dL by day 13.
Hyperglycemia was associated with a reduction in
insulin levels, which returned to normal by day 30 to 35
(Figure 7). HbA1c concentrations were not affected by
treatment (5.6 ± 0.4% at baseline and 5.6 ± 0.3% three
months after stopping the drug). Serum IGF-I decreasedFigure 7 Effects of treatment with pasireotide on glucose, insulin, an
plasma glucose and serum insulin during the 10-day treatment with pasire
IGF-I before, at the end of treatment, and 90 days after treatment with pasin all patients, confirming adherence to treatment, al-
though it remained within the age-specific normal
range in 11 (84.6%). It returned to normal by three months
(Figure 5B).
Discussion
In recent years a number of IGF-I inhibitors have been
tested in the treatment of various carcinomas. Bothd insulin-like growth factor -1 (IGF-I). (A) Mean concentrations of
otide and the subsequent follow up. (B) Mean serum concentration of
ireotide. Error bars are SDs in both graphs.
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inhibitors of its tyrosine kinase activity have been
employed, usually together with other anti-cancer drugs
[13-17]. Efficacy has been mixed, at best. The results led
Yee to liken IGF-I inhibition to ‘the baby or the bath-
water’ [18]. Those studies were largely carried out in pa-
tients with advanced solid tumors.
We have approached IGF-I inhibition from a different
vantage point. Studies from our laboratory show that
growth hormone-induced IGF-I is essential for mammary
development in mice and rats [6,7], and that growth
hormone (GH), or IGF-I absence or inhibition, block
development [12,19]. In addition, administration of GH
plus physiological concentrations of estradiol was found
to cause mammary hyperplasia in hypophysectomised,
oophorectomized rats [9] and pasireotide prevented it.
Pasireotide is uniquely effective in inhibiting the action of
IGF-I in the mammary gland. Like the older somatostatin
analogs, octreotide and lanreotide, it reduces GH secretion
from the pituitary gland, which results in decreased liver
expression of IGF-I, and thereby reduced serum levels. By
virtue of its broader somatostatin receptor affinity profile,
however, pasireotide also potently inhibits IGF-I activity
directly in the mammary gland, likely by stimulating the
expression of IGF-I binding protein 5, which preferentially
binds to IGF-I making it unavailable for its receptor [12].
Although a side-by-side comparison of pasireotide with
tamoxifen was not done, the experiments provided evi-
dence that pasireotide was at least as, or possibly more,
effective than tamoxifen in preventing hormone-induced
hyperplasia [9]. It should be pointed out that we did not
measure IGF-2 because specimens became unavailable.
Anti-estrogen chemoprevention in patients with atypical
lesions significantly decreases development of carcinoma
[2]. In this study we tested IGF-I inhibition for breast can-
cer prevention in humans, by analyzing the effect of pasir-
eotide on different types of precancerous lesions including
proliferative lesions, atypical hyperplasia and also one case
of ductal carcinoma in situ. Atypical hyperplasias are char-
acterized by genetic alterations and gene expression pro-
files similar to those of invasive carcinomas [20] and are
associated with an increased risk for developing cancer
[21]. We postulated that earlier lesions such as atypical
hyperplasia would maintain their responsiveness to IGF-I
inhibition. This proof-of-principal trial used surrogate bio-
logical endpoints (proliferation and apoptosis) in patients
with atypical breast lesions to test the efficacy of IGF-I in-
hibition. Indeed, pasireotide significantly decreased cell
proliferation in proliferative lesions and AH during 10 days
of treatment. Importantly, pasireotide also reduced the per-
centage of proliferating cells in one case of DCIS.
Phase 1 studies typically do not include randomized
placebo-controlled arms. To help confirm observations in
the treated group we examined core and excision biopsiesfrom 15 women with precancerous lesions of proliferative
disease and atypical hyperplasia, who underwent excision
biopsies as standard of care. They did not receive pasi-
reotide between core and excision biopsies. There was no
significant difference in proliferation from the hypothesis
of random change between core and excision biopsies.
Although the cell proliferation indices were low in both
treated and untreated patients, the lack of a reduction in
cell proliferation in the untreated patients in excision
biopsies helps support the Ki67 results. Deregulated pro-
liferation underlies the entire spectrum of precancerous
breast lesions and it is also a main feature of established
cancer [22]. Therefore, IGF-I inhibition by means of pasir-
eotide affected a key event in breast carcinogenesis.
Decreased proliferation is also thought to be a main
mechanism by which estrogen inhibitors may prevent
the development and inhibit the progression of breast
cancer. Although the effects of pasireotide and estrogen
inhibitors on cell proliferation have not been compared
directly, the magnitude of change in published reports
suggests that the effect of estrogen inhibitors is similar to
that of pasireotide [23-26].
Recent reports indicate that analysis of ki67 can be
highly variable between different readers and at different
institutions [27]. To determine whether our pathology col-
laborators also experienced reading variability, we had two
of them (BS and FS) independently read before- and after-
treatment slides for cell proliferation in 10 patients (mean
age 54.8 ± 4.7 years) and 23 untreated controls (mean age:
54.5 ± 9.1 years). The inter-rater agreement was excellent,
Pasireotide was also found to significantly increase
apoptosis in proliferative lesions, AH, and in one case of
DCIS. Apoptosis is particularly effective in eliminating
aberrant cells which might play a role in cancer preven-
tion. This effect may be secondary to the inhibition of
IGF-I, which is anti-apoptotic [8], but also to an IGF-I-
independent activity of pasireotide, as activation of the
somatostatin receptors has been shown to directly induce
cell cycle arrest and apoptosis in other tissues [28]. Tam-
oxifen is also pro-apoptotic in breast cancer cells, as well
as in experimental tumors in rats [29,30]. However, the
effects of tamoxifen on apoptosis in women in prevention
trials are not as well-documented, making comparison
difficult [25,31].
These studies show that pasireotide directly blocks the
IGF-I receptor activity, which in turn, prevents free IGF-I
binding to the IGF-1R [12]. It also increases IGF binding
protein 5, which is thought to preferentially bind to local
IGF-I more than to the IGF-1R [9]. Whether this event
occurs after blockade of the IGF-1R or is independent is
not known. That reduction in phosphorylated AKT and
ERK 1/2, which are main intracellular mediators of IGF-I
downstream IGF-I pathway, may explain the decrease in
cell proliferation and increase in apoptosis [8,32]. Specific
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for treatment of breast cancer [32].
Pasireotide is presently approved for treatment of
Cushing’s disease with the caveat that it can cause hyper-
glycemia or diabetes, or worsen existing diabetes [33]. The
present trial provides evidence that the hyperglycemia of
pasireotide is caused by a reduction in serum insulin, and
another recent study found that the reduction of insulin is
accompanied by a reduction in glucagon-like peptide-1
(GLP-1) and glucose-dependent insulinotropic peptide
(GIP) [34]. These effects are clearly more problematic
in patients with Cushing’s disease or women with under-
lying diabetes than they would be in otherwise normal
individuals.
Minimal to moderate hyperglycemia would not pose
a major risk to these patients during relatively short
periods. In contrast, prolonged exposure might do so.
Therefore, it would be important to prevent or lessen
the impact of pasireotide on hyperglycemia. Possible
approaches might include, altering the dose of pasireotide,
adding glucagon-like peptide 1 agonists, or metformin [35],
and/or using pasireotide intermittently. Preclinical studies
in Brca1-deficient mice have shown that intermittent ad-
ministration of pasireotide maintains its inhibitory effect
on cell proliferation for at least 3 weeks after discontinu-
ing medication (as yet unpublished). Our trial provides
evidence that hyperglycemia disappears rapidly on stop-
ping pasireotide. Thus, hyperglycemia might be decreased
by reducing exposure to medication. Pasireotide is also
available in a once-a-month preparation. However, until
further studies are carried out, and a means of dealing
with hyperglycemia is established, it is premature to sug-
gest the use of pasireotide for breast cancer prevention.
Conclusion
In conclusion, these results provide proof of principle that
inhibiting the effect of IGF-I downstream of the IGF-I
pathway with pasireotide causes a decrease in cell prolifer-
ation and an increase in apoptosis in precancerous breast
lesions. Further trials might support the concept that IGF-I
inhibition might serve as a chemoprevention tool for
breast cancer, especially in patients unable to tolerate
direct estrogen inhibition.
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